# Questions From the Research Record > Tissue-Repair Peptide FAQ — BPC-157, TB-500, KLOW — Formula1 Peptides — Frequently asked questions about BPC-157, TB-500, and KLOW, answered from the peer-reviewed literature with citations. No dosing advice. **RECOVERY & TISSUE REPAIR / FAQ** Direct, citation-anchored answers to the questions readers most often bring to BPC-157, TB-500, and KLOW. ## What does BPC-157 do in the body? In animal and cell studies, BPC-157 is described as cytoprotective — it appears to protect and help repair tissue, with its best-characterized mechanism being up-regulation of the VEGFR2 receptor and downstream VEGFR2-Akt-eNOS signaling, which drives new blood-vessel growth and faster blood-flow recovery in ischemic tissue [4]. The foundational studies also showed it reduces gastric-ulcer size and speeds ulcer healing in rats [5]. Human evidence is limited to one small IV safety pilot [1] and a handful of other small pilots noted in a 2025 review [2]. ## Is BPC-157 a growth hormone? No. BPC-157 is a synthetic pentadecapeptide derived from a gastric-juice protein, not a growth hormone and not structurally related to one. It has been reported in cultured tendon-fibroblast studies to sensitize the growth-hormone receptor, meaning it may make cells more responsive to existing growth-hormone signaling, but that is a distinct mechanism from being a growth hormone itself, and its long-term implications are not established in humans. ## Does BPC-157 work immediately? No controlled human trial has measured how quickly BPC-157 produces an effect. Community reports describe tendon, ligament, and joint improvements appearing within one to three weeks, and gut-symptom improvements within one to two weeks — but these are anecdotal, not clinical evidence, and individual reports vary widely. The only controlled human data available is a short IV safety pilot that measured tolerability, not effect timing [1]. ## Does BPC-157 damage the liver? The only human safety data available — a two-person IV pilot at doses up to 20 mg — found no measurable changes in hepatic (liver) biomarkers, alongside no changes in cardiac, renal, thyroid, or glucose markers [1]. That is a very small sample size and not proof of long-term liver safety; a 2025 review notes that rigorous, large-scale human trials are still lacking and recommends treating BPC-157 as investigational [2]. ## What is TB-500? TB-500 is the commercial name for Ac-LKKTETQ, a synthetic, N-acetylated seven-amino-acid fragment of the natural protein thymosin beta-4 — specifically residues 17–23, the conserved actin-binding motif shared by the beta-thymosin protein family. It is sold as a research chemical and, separately, has veterinary designations (TB-500 / TB1000) in some contexts. It is not FDA-approved and is prohibited in competitive sport by WADA [6]. ## What does TB-500 stand for and what does TB stand for in TB-500? "TB" refers to thymosin beta, the parent protein family, and "500" is a commercial designation, not a molecular-weight or dosage figure. TB-500 denotes the synthetic Ac-LKKTETQ fragment (residues 17–23) of thymosin beta-4 — it is not an official scientific abbreviation used in the peer-reviewed literature, which generally refers to the parent protein as thymosin beta-4 (Tβ4) or by its gene name, TMSB4X. ## What is TB-500 used for in research? In its full-length parent-protein form, thymosin beta-4 has been studied for wound healing and re-epithelialization [12], cardiac repair after ischemic injury [11], and neurological recovery after stroke [7], with a Phase 1 human safety trial establishing tolerability at IV doses up to 1,260 mg [9]. The short TB-500 fragment sold commercially is studied by suppliers and research communities mainly for tendon, ligament, and soft-tissue repair, but no completed controlled human trial of the fragment itself exists for any indication [6]. ## Does TB-500 work for muscle tears and recovery from exercise? There is no completed controlled human trial testing the TB-500 fragment for muscle tears or exercise recovery. A 2026 Sports Medicine review of unapproved musculoskeletal peptides, including TB-500, found favorable tissue-repair signals in animal models but scarce human safety data and cautioned that potential for serious harm exists outside regulatory oversight [6]. Community reports of faster-feeling muscle and tendon recovery are common but anecdotal, not clinical evidence, and vary widely between individuals. ## What is KLOW peptide? KLOW is a four-peptide research blend — a single co-formulated vial containing KPV, GHK-Cu, BPC-157, and TB-500 at fixed mass ratios. It is not one molecule; the four peptides remain chemically distinct in solution. No controlled study has ever tested the combination itself — every claim about how the four work together is a mechanistic extrapolation from research on each peptide studied alone. ## What is KLOW peptide used for? In research and community contexts, KLOW is discussed for the same broad tissue-repair goals as its individual components: tendon, ligament, and joint recovery (from BPC-157 and TB-500), skin and matrix support (from GHK-Cu) [13][14], and reduced inflammatory signaling (from KPV) [15]. Because the blend itself has never been studied, none of this is established use — it is a description of what each ingredient has been studied for individually. ## Where do you inject KLOW peptide? This site does not provide injection guidance, administration routes, or any other instructions for using KLOW or any of its components, because it is not an approved medicine and no clinical protocol exists for it. Anyone encountering administration instructions online should recognize that none of it comes from a controlled clinical study — the blend has never been tested in one. ## How much KLOW peptide per day? This site does not recommend a dose for KLOW or any of its components. No dosing protocol for the four-peptide combination has been established in any controlled study, and the individual components clear from the body at very different rates — BPC-157's elimination half-life is under 30 minutes, while the tripeptides KPV and GHK-Cu clear even faster [3] — which is itself a caution against assuming a single dosing schedule could deliver matched exposure of all four. --- Formula1 Peptides is an independent tissue-repair literature review, not a clinic, not a formulator, and not a substitute for reading the cited studies yourself.